Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 51, Issue 9

Issues

Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification1)

Anna Durigova
  • Department of Medical Oncology, CRLC Val d’Aurelle, Montpellier, France
  • Anna Durigova and Pierre-Jean Lamy contributed equally to this work.
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Pierre-Jean Lamy
  • Corresponding author
  • Biothèque-Biological Resource Center, CRLC Val d’Aurelle, Montpellier, France
  • Anna Durigova and Pierre-Jean Lamy contributed equally to this work.
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Simon Thezenas / Stephane Pouderoux / Frédéric Montels / Gilles Romieu / Marian Gutowski / William Jacot
Published Online: 2013-06-20 | DOI: https://doi.org/10.1515/cclm-2013-0031

Abstract

Background: Anemia, a frequent and deleterious condition in patients with cancer, is mainly caused by chemotherapy toxicity, iron deficiency, or inflammation. We evaluated the baseline iron metabolism biomarkers and their association with anemia occurrence during chemotherapy in patients with early breast cancer (EBC).

Methods: In this monocentric retrospective study, classical iron metabolism markers and new biomarkers as well as sTfR and hepcidin were assessed at baseline in 347 patients with EBC who received a sequential taxane and anthracycline-based regimen between April 2007 and October 2009. Hemoglobin level was measured every 21 days.

Results: Thirty-five patients had baseline iron deficiency and 13 inflammatory iron sequestration. In multivariate analysis, only high sTfR (OR=27.6, p<0.001, 95% CI 8.74–87) and pre-menopausal status (OR=7.3, 95% CI 0.04–0.43, p=0.001) remained statistically associated with iron deficiency. High hepcidin values and inflammatory iron sequestration were significantly associated (p=0.032). In total 6.1% patients had baseline anemia and 86.2% patients developed anemia during chemotherapy (41 had grade ≥2 anemia). Baseline hemoglobin below 13 g/dL and low hepcidin levels were the two independent predictive factors of severe anemia.

Conclusions: In early breast cancer treated by chemotherapy, only baseline hemoglobin and hepcidin levels are independent predictive factors of anemic syndrome occurrence.

This article offers supplementary material which is provided at the end of the article.

Keywords: anemia; breast cancer; hemoglobin; hepcidin; iron metabolism; soluble transferrin receptor

References

  • 1.

    Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306.CrossrefPubMedGoogle Scholar

  • 2.

    Guardiola E, Morschhauser F, Zambrowski JJ, Antoine EC. Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment). Bull Cancer 2007;94:907–14.Google Scholar

  • 3.

    Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43–6.PubMedGoogle Scholar

  • 4.

    Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37:14–7.PubMedCrossrefGoogle Scholar

  • 5.

    Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001;84:31–7.CrossrefPubMedGoogle Scholar

  • 6.

    Glaspy J. Anemia and fatigue in cancer patients. Cancer 2001;92:1719–24.PubMedCrossrefGoogle Scholar

  • 7.

    Dicato M, Harper P. The optimal hemoglobin level in the cancer patient. Semin Oncol 2002;29:88–91.PubMedGoogle Scholar

  • 8.

    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–23.PubMedCrossrefGoogle Scholar

  • 9.

    Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1:S4–8.CrossrefPubMedGoogle Scholar

  • 10.

    Koulaouzidis A, Said E, Cottier R, Saeed AA. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis 2009;18:345–52.PubMedGoogle Scholar

  • 11.

    Jandl JH, Katz JH. The plasma-to-cell cycle of transferrin. J Clin Invest 1963;42:314–26.CrossrefPubMedGoogle Scholar

  • 12.

    Trowbridge IS, Omary MB. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci USA 1981;78:3039–43.CrossrefGoogle Scholar

  • 13.

    Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1991;89:1052–7.Google Scholar

  • 14.

    Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573–8.PubMedCrossrefGoogle Scholar

  • 15.

    Baynes RD. Assessment of iron status. Clin Biochem 1996;29:209–15.PubMedCrossrefGoogle Scholar

  • 16.

    Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007;18:394–400.CrossrefWeb of SciencePubMedGoogle Scholar

  • 17.

    Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425–33.PubMedWeb of ScienceGoogle Scholar

  • 18.

    Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271–6.PubMedGoogle Scholar

  • 19.

    Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113:1251–3.PubMedGoogle Scholar

  • 20.

    Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003;101:4148–54.PubMedCrossrefGoogle Scholar

  • 21.

    Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol 2010;2010:358283.PubMedGoogle Scholar

  • 22.

    Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037–44.PubMedGoogle Scholar

  • 23.

    Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002;25:371–9.PubMedCrossrefGoogle Scholar

  • 24.

    Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, et al. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer 2008;16:67–74.CrossrefGoogle Scholar

  • 25.

    Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, et al. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003;79:347–53.CrossrefPubMedGoogle Scholar

  • 26.

    Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 2005;6:856–63.PubMedCrossrefGoogle Scholar

  • 27.

    Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 1990;88:205–9.CrossrefPubMedGoogle Scholar

  • 28.

    Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011;60:1309–16.CrossrefPubMedGoogle Scholar

  • 29.

    Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986;145:657–63.PubMedGoogle Scholar

  • 30.

    Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, Hulten L. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol 1993;85:787–98.CrossrefGoogle Scholar

  • 31.

    Cogswell ME, Looker AC, Pfeiffer CM, Cook JD, Lacher DA, Beard JL, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003–2006. Am J Clin Nutr 2009;89:1334–42.Web of ScienceGoogle Scholar

  • 32.

    Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study – design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants. Control Clin Trials 1998;19:336–51.Google Scholar

  • 33.

    Mannello F, Tonti GA, Simone P, Ligi D, Medda V. Iron-binding proteins and C-reactive protein in nipple aspirate fluids: role of iron-driven inflammation in breast cancer microenvironment? Am J Transl Res 2010;3:100–13.PubMedGoogle Scholar

  • 34.

    Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997;1331:1–40.Google Scholar

  • 35.

    Pinnix ZK, Miller LD, Wang W, D′Agostino R Jr., Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 4;2:43–56.Web of ScienceGoogle Scholar

  • 36.

    Huang X, Fung ET, Yip C, Zeleniuch-Jacquotte A. Serum prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women. Blood Cells Mol Dis 2008;41:265–9.CrossrefWeb of SciencePubMedGoogle Scholar

  • 37.

    Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650–69.CrossrefPubMedGoogle Scholar

  • 38.

    Peters-Engl C, Cassik P, Schmidt I, Denison U, Medl M, Pokieser W, et al. Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer. Acta Oncol 2005;44:129–33.CrossrefGoogle Scholar

  • 39.

    Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726–41.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 40.

    Swinkels DW, Wetzels JF. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 2008;23:2450–3.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Dr. Pierre-Jean Lamy, Department of Biology and Oncogenetic, CRLC Val d’Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France, Phone: +33 467613139, Fax: +33 467632873


Received: 2013-01-10

Accepted: 2013-05-30

Published Online: 2013-06-20

Published in Print: 2013-09-01


This article was presented in part at the 17th International Meeting of the European Society of Gynaecological Oncology, Milan, Italy, September 11–14, 2011.


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 51, Issue 9, Pages 1833–1841, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-0031.

Export Citation

©2013 by Walter de Gruyter Berlin Boston.Get Permission

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
F. Lebrun, J. Klastersky, D. Levacq, Y. Wissam, and M. Paesmans
Supportive Care in Cancer, 2017, Volume 25, Number 7, Page 2313
[2]
Chiara Maura Ciniselli, Maida De Bortoli, Elena Taverna, Luca Varinelli, Sara Pizzamiglio, Silvia Veneroni, Chiara Bonini, Rosaria Orlandi, Paolo Verderio, and Italia Bongarzone
Expert Review of Proteomics, 2015, Volume 12, Number 6, Page 695
[3]
Wenli Guo, Shuping Zhang, Yue Chen, Daoqiang Zhang, Lin Yuan, Haibo Cong, and Sijin Liu
Acta Biochimica et Biophysica Sinica, 2015, Volume 47, Number 9, Page 703
[4]
Pierre-Jean Lamy, Anna Durigova, and William Jacot
Clinica Chimica Acta, 2014, Volume 434, Page 34

Comments (0)

Please log in or register to comment.
Log in